Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease

Rajaraman Eri, Krithika N. Kodumudi, Don John Summerlin, Mythily Srinivasan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Human inflammatory bowel disease (IBD) is a chronic condition mediated by aberrant immune responses to the luminal antigens by activated CD4+ T cells. The CD80/CD86: CD28/CD152 costimulatory pathways transmit signals critical for T cell activation and suppression. Macrophages and epithelial cells are the chief antigen-presenting cells in the gut. Macrophages from the IBD colon express significantly elevated levels of CD80 and CD86 costimulatory molecules. The CD28-CD80 interaction primarily participates in breaking the tolerance and inducing the immune response in murine models of colitis. Blockade of CD80-costimulatory axis is an attractive strategy in the treatment of IBD. Methods: Incorporating the structural information of the CD80: CD152 complex together with the preferences of interface residues to form polyproline type II helix, we designed novel peptide agents that selectively blocked CD80 receptor interactions. Results: Administration of CD80 blocking agent at the time of adoptive transfer prevented the SCID mice from CD4+CD45Rbhigh T-cell mediated colitis. Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. The colons of the mice receiving the CD80 blocking agent appeared unaffected macroscopically and exhibited negligible microscopic inflammation. The CD80-CAP treatment was associated with significantly reduced Th1 cytokines in the colon. Conclusions: The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response.

Original languageEnglish (US)
Pages (from-to)458-470
Number of pages13
JournalInflammatory Bowel Diseases
Volume14
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Colitis
Inflammatory Bowel Diseases
Colon
Inflammation
T-Lymphocytes
Macrophages
Cytokines
Immune Tolerance
CD4 Antigens
SCID Mice
Adoptive Transfer
Antigen-Presenting Cells
Crohn Disease
Signal Transduction
Therapeutics
Epithelial Cells
Peptides
CD80-CAP

Keywords

  • CD80 blockade
  • IBD
  • Murine model

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Suppression of colon inflammation by CD80 blockade : Evaluation in two murine models of inflammatory bowel disease. / Eri, Rajaraman; Kodumudi, Krithika N.; Summerlin, Don John; Srinivasan, Mythily.

In: Inflammatory Bowel Diseases, Vol. 14, No. 4, 04.2008, p. 458-470.

Research output: Contribution to journalArticle

@article{b5ac3a0cbcd24f59b7f5270deb00c8d7,
title = "Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease",
abstract = "Background: Human inflammatory bowel disease (IBD) is a chronic condition mediated by aberrant immune responses to the luminal antigens by activated CD4+ T cells. The CD80/CD86: CD28/CD152 costimulatory pathways transmit signals critical for T cell activation and suppression. Macrophages and epithelial cells are the chief antigen-presenting cells in the gut. Macrophages from the IBD colon express significantly elevated levels of CD80 and CD86 costimulatory molecules. The CD28-CD80 interaction primarily participates in breaking the tolerance and inducing the immune response in murine models of colitis. Blockade of CD80-costimulatory axis is an attractive strategy in the treatment of IBD. Methods: Incorporating the structural information of the CD80: CD152 complex together with the preferences of interface residues to form polyproline type II helix, we designed novel peptide agents that selectively blocked CD80 receptor interactions. Results: Administration of CD80 blocking agent at the time of adoptive transfer prevented the SCID mice from CD4+CD45Rbhigh T-cell mediated colitis. Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. The colons of the mice receiving the CD80 blocking agent appeared unaffected macroscopically and exhibited negligible microscopic inflammation. The CD80-CAP treatment was associated with significantly reduced Th1 cytokines in the colon. Conclusions: The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response.",
keywords = "CD80 blockade, IBD, Murine model",
author = "Rajaraman Eri and Kodumudi, {Krithika N.} and Summerlin, {Don John} and Mythily Srinivasan",
year = "2008",
month = "4",
doi = "10.1002/ibd.20344",
language = "English (US)",
volume = "14",
pages = "458--470",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Suppression of colon inflammation by CD80 blockade

T2 - Evaluation in two murine models of inflammatory bowel disease

AU - Eri, Rajaraman

AU - Kodumudi, Krithika N.

AU - Summerlin, Don John

AU - Srinivasan, Mythily

PY - 2008/4

Y1 - 2008/4

N2 - Background: Human inflammatory bowel disease (IBD) is a chronic condition mediated by aberrant immune responses to the luminal antigens by activated CD4+ T cells. The CD80/CD86: CD28/CD152 costimulatory pathways transmit signals critical for T cell activation and suppression. Macrophages and epithelial cells are the chief antigen-presenting cells in the gut. Macrophages from the IBD colon express significantly elevated levels of CD80 and CD86 costimulatory molecules. The CD28-CD80 interaction primarily participates in breaking the tolerance and inducing the immune response in murine models of colitis. Blockade of CD80-costimulatory axis is an attractive strategy in the treatment of IBD. Methods: Incorporating the structural information of the CD80: CD152 complex together with the preferences of interface residues to form polyproline type II helix, we designed novel peptide agents that selectively blocked CD80 receptor interactions. Results: Administration of CD80 blocking agent at the time of adoptive transfer prevented the SCID mice from CD4+CD45Rbhigh T-cell mediated colitis. Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. The colons of the mice receiving the CD80 blocking agent appeared unaffected macroscopically and exhibited negligible microscopic inflammation. The CD80-CAP treatment was associated with significantly reduced Th1 cytokines in the colon. Conclusions: The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response.

AB - Background: Human inflammatory bowel disease (IBD) is a chronic condition mediated by aberrant immune responses to the luminal antigens by activated CD4+ T cells. The CD80/CD86: CD28/CD152 costimulatory pathways transmit signals critical for T cell activation and suppression. Macrophages and epithelial cells are the chief antigen-presenting cells in the gut. Macrophages from the IBD colon express significantly elevated levels of CD80 and CD86 costimulatory molecules. The CD28-CD80 interaction primarily participates in breaking the tolerance and inducing the immune response in murine models of colitis. Blockade of CD80-costimulatory axis is an attractive strategy in the treatment of IBD. Methods: Incorporating the structural information of the CD80: CD152 complex together with the preferences of interface residues to form polyproline type II helix, we designed novel peptide agents that selectively blocked CD80 receptor interactions. Results: Administration of CD80 blocking agent at the time of adoptive transfer prevented the SCID mice from CD4+CD45Rbhigh T-cell mediated colitis. Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. The colons of the mice receiving the CD80 blocking agent appeared unaffected macroscopically and exhibited negligible microscopic inflammation. The CD80-CAP treatment was associated with significantly reduced Th1 cytokines in the colon. Conclusions: The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response.

KW - CD80 blockade

KW - IBD

KW - Murine model

UR - http://www.scopus.com/inward/record.url?scp=42449098038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449098038&partnerID=8YFLogxK

U2 - 10.1002/ibd.20344

DO - 10.1002/ibd.20344

M3 - Article

C2 - 18186109

AN - SCOPUS:42449098038

VL - 14

SP - 458

EP - 470

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -